Every year, Taiwan purchases about 7 million doses of influenza vaccines. These vaccines are administered free of charge in batches, starting this month with people aged 65 or older, followed by the second batch next month for those older than 50. By the end of the year, about 5 million to 6 million doses would have been used. Starting from the New Year, vaccinations are to be opened up to anyone.
Of course, the uptake of vaccines varies from year to year. This year, due to the “immunity debt” factor, a lot of people have recently been coming down with the flu, and there is quite a strong demand for flu vaccines.
In previous years, people have wanted to be vaccinated with imported flu vaccines such as those made by French-based Sanofi or imported from Germany by TTY Biopharm, while those made by Taiwan’s Adimmune Corp have not been quite so popular.
However, as a physician, I always explain to my patients that Adimmune’s vaccine research and development is done under Japanese guidance and the quality is good. I assure them that I have been administering Adimmune’s vaccines for many years and they can put their faith in them.
Most patients are willing to accept this advice, so our first-line clinic has been doing this for many years without any arguments or disputes.
This year, a flu vaccine marketed by Taiwan’s Medigen Vaccine Biologics Corp has been added to the list. The vaccine is made by South Korea’s GC Biopharma and packaged into vials by Medigen’s pharmaceuticals factory in Taiwan, and most experts agree that it is of very good quality.
Unfortunately, due to ideological and political differences in Taiwan, some people have no faith in Medigen, while others have ulterior motives for undermining people’s faith.
Consequently, many parents and elderly people have stumbled upon Internet posts and messages that worry them. Uncertain what to believe, they would rather be safe than sorry.
At the same time, some mayors and county commissioners want to respect parents’ choices, in some cases even issuing clear instructions that schoolchildren should not be given Medigen vaccines, and this has made many elderly people even more doubtful about getting a Medigen jab.
However, the Centers for Disease Control (CDC) has for many years stipulated that the public cannot choose between vaccines and must take whichever is available. You might think that this year’s addition of Medigen vaccines would make things easier, but it is conversely causing more of a headache for clinics, even eroding doctor-patient trust.
The authorities have only bought 700,000 doses of the Medigen vaccine this year. Rather than making elderly people worried and afraid, making life difficult for clinics and spoiling the trust between doctors and patients, it would be better to assign the Medigen vaccines to the last batch so they could be used early next year, when free vaccines become available for the under-50s. That would come as a big relief for everyone.
The CDC should not insist that the public not be able to choose their vaccines and have to accept the Medigen jab if that is the only one available. At best that would cause widespread resentment, and at worst it would make elderly people hesitant about getting vaccinated, which would cause some of them to end up seriously ill in a hospital or even endanger their lives. It is high time for the CDC to give this issue a thorough rethink.
Wang Fong-yu is a standing director of the Taiwan Medical Association.
Translated by Julian Clegg
Trying to force a partnership between Taiwan Semiconductor Manufacturing Co (TSMC) and Intel Corp would be a wildly complex ordeal. Already, the reported request from the Trump administration for TSMC to take a controlling stake in Intel’s US factories is facing valid questions about feasibility from all sides. Washington would likely not support a foreign company operating Intel’s domestic factories, Reuters reported — just look at how that is going over in the steel sector. Meanwhile, many in Taiwan are concerned about the company being forced to transfer its bleeding-edge tech capabilities and give up its strategic advantage. This is especially
US President Donald Trump’s second administration has gotten off to a fast start with a blizzard of initiatives focused on domestic commitments made during his campaign. His tariff-based approach to re-ordering global trade in a manner more favorable to the United States appears to be in its infancy, but the significant scale and scope are undeniable. That said, while China looms largest on the list of national security challenges, to date we have heard little from the administration, bar the 10 percent tariffs directed at China, on specific priorities vis-a-vis China. The Congressional hearings for President Trump’s cabinet have, so far,
The US Department of State has removed the phrase “we do not support Taiwan independence” in its updated Taiwan-US relations fact sheet, which instead iterates that “we expect cross-strait differences to be resolved by peaceful means, free from coercion, in a manner acceptable to the people on both sides of the Strait.” This shows a tougher stance rejecting China’s false claims of sovereignty over Taiwan. Since switching formal diplomatic recognition from the Republic of China to the People’s Republic of China in 1979, the US government has continually indicated that it “does not support Taiwan independence.” The phrase was removed in 2022
US President Donald Trump, US Secretary of State Marco Rubio and US Secretary of Defense Pete Hegseth have each given their thoughts on Russia’s war with Ukraine. There are a few proponents of US skepticism in Taiwan taking advantage of developments to write articles claiming that the US would arbitrarily abandon Ukraine. The reality is that when one understands Trump’s negotiating habits, one sees that he brings up all variables of a situation prior to discussion, using broad negotiations to take charge. As for his ultimate goals and the aces up his sleeve, he wants to keep things vague for
RSS